Profile data is unavailable for this security.
About the company
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
- Revenue in USD (TTM)0.00
- Net income in USD-199.06m
- Incorporated2000
- Employees251.00
- LocationXenon Pharmaceuticals Inc3650 Gilmore WayVANCOUVER V5G 4W8CanadaCAN
- Phone+1 (604) 484-3300
- Fax+1 (604) 484-3450
- Websitehttps://www.xenon-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dyne Therapeutics Inc | 0.00 | -257.60m | 2.86bn | 152.00 | -- | 3.68 | -- | -- | -3.58 | -3.58 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -47.82 | -52.81 | -50.15 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| ACADIA Pharmaceuticals Inc | 929.24m | 128.51m | 2.93bn | 620.00 | 22.78 | 5.09 | 20.80 | 3.15 | 0.7753 | 0.7753 | 5.60 | 3.47 | 1.15 | 1.91 | 9.73 | 1,556,509.00 | 15.97 | -27.50 | 24.34 | -32.73 | 91.61 | 95.62 | 13.83 | -38.35 | 2.11 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Vera Therapeutics Inc | 0.00 | -107.85m | 2.98bn | 72.00 | -- | 8.04 | -- | -- | -2.20 | -2.20 | 0.00 | 5.98 | 0.00 | -- | -- | 0.00 | -36.41 | -- | -39.42 | -- | -- | -- | -- | -- | -- | -- | 0.1329 | -- | -- | -- | -7.79 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 90.86m | -410.00m | 3.21bn | 557.00 | -- | 4.17 | -- | 35.36 | -1.50 | -1.50 | 0.3273 | 2.54 | 0.0986 | 3.24 | -- | 163,120.30 | -44.48 | -51.47 | -50.17 | -57.56 | 14.75 | -- | -451.25 | -137,873.80 | 3.90 | -- | 0.0013 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Amicus Therapeutics, Inc. | 493.67m | -104.69m | 3.28bn | 517.00 | -- | 18.36 | -- | 6.65 | -0.3461 | -0.3461 | 1.63 | 0.5987 | 0.6367 | 0.5739 | 5.76 | 954,876.20 | -13.50 | -30.65 | -17.12 | -36.55 | 89.99 | 88.94 | -21.21 | -86.10 | 2.42 | 0.3214 | 0.6853 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Kymera Therapeutics Inc | 87.56m | -167.47m | 3.30bn | 184.00 | -- | 3.69 | -- | 37.68 | -2.33 | -2.33 | 1.26 | 13.79 | 0.1103 | -- | 34.37 | 468,251.30 | -21.10 | -23.03 | -22.98 | -27.64 | -- | -- | -191.26 | -207.82 | -- | -- | 0.0035 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| MoonLake Immunotherapeutics | 0.00 | -80.77m | 3.31bn | 50.00 | -- | 6.69 | -- | -- | -1.29 | -1.29 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -16.25 | -- | -18.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 32.87m | 727.43m | 3.37bn | 383.00 | 4.81 | 2.07 | 4.59 | 102.47 | 12.28 | 11.37 | 0.5778 | 28.53 | 0.0235 | 0.1598 | 15.31 | 85,825.06 | 51.98 | -29.54 | 55.50 | -31.88 | 89.38 | -- | 2,212.98 | -3,826.10 | 8.77 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -199.06m | 3.41bn | 251.00 | -- | 4.03 | -- | -- | -2.74 | -2.74 | 0.00 | 11.15 | 0.00 | -- | -- | 0.00 | -25.38 | -20.71 | -26.37 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Edgewise Therapeutics Inc | 0.00 | -115.88m | 3.41bn | 97.00 | -- | 6.67 | -- | -- | -1.53 | -1.53 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -26.88 | -- | -27.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -118.49m | 3.57bn | 91.00 | -- | 4.48 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Alvotech SA | 308.73m | -618.38m | 3.83bn | 999.00 | -- | -- | -- | 12.39 | -2.65 | -2.65 | 1.28 | -2.27 | 0.312 | 1.80 | 3.66 | 309,038.00 | -62.49 | -- | -222.85 | -- | 48.79 | -- | -200.30 | -- | 0.1569 | -0.2323 | 2.04 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Immunitybio Inc | 1.31m | -597.65m | 3.88bn | 622.00 | -- | -- | -- | 2,966.13 | -0.9356 | -0.9356 | 0.0021 | -1.01 | 0.0036 | -- | 0.49 | 2,082.80 | -162.54 | -112.76 | -1,927.61 | -316.07 | -- | -- | -45,701.07 | -37,700.74 | 3.88 | -2.33 | 3.69 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
Data as of Nov 08 2024. Currency figures normalised to Xenon Pharmaceuticals Inc's reporting currency: US Dollar USD
45.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avoro Capital Advisor LLCas of 30 Jun 2024 | 5.67m | 7.48% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 5.52m | 7.28% |
| Driehaus Capital Management LLCas of 30 Jun 2024 | 4.42m | 5.83% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 3.71m | 4.90% |
| Commodore Capital LPas of 30 Jun 2024 | 2.75m | 3.64% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 2.68m | 3.54% |
| Braidwell LPas of 30 Jun 2024 | 2.56m | 3.38% |
| Polar Capital LLPas of 30 Jun 2024 | 2.54m | 3.35% |
| Capital Research & Management Co. (International Investors)as of 30 Jun 2024 | 2.48m | 3.27% |
| Paradigm BioCapital Advisors LPas of 30 Jun 2024 | 2.04m | 2.70% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
